Compare Summit Therapeutics Inc (SMMT) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Thomson Reuters Corp — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Thomson Reuters Corp trades at $103.21 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 3.2× Summit Therapeutics Inc's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Thomson Reuters Corp for 63 Days on average.
| SMMT | TRI | |
|---|---|---|
Market Cap | $13.71B | $43.89B |
Volume | 6,173,057 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $26.38 | $163.45 |
52-Week Low | $12.43 | $76.55 |
Typical Hold Time | 16 Days | 63 Days |
Enterprise Value | $13.04B | $46.51B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
Thomson Reuters (TRI) trades at $101.55, up 2.29% today, with a bullish technical signal and strong analyst support. The company shows robust profitability with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, enhancing its competitive edge in legal and tax solutions.
Outlook remains positive with a consensus price target of $133.25, though risks include a recent cybersecurity incident and fluctuating cash flows. Earnings momentum is solid with two recent beats, but valuation multiples like a P/E of 26.75 suggest premium pricing, requiring sustained growth to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
